Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDQuarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
---|---|---|---|---|
Q1 2024 | 3 | -$2.42 | -$0.54 | -$1.25 |
Q2 2024 | 2 | -$2.14 | -$0.48 | -$1.11 |
Q3 2024 | 3 | -$1.54 | -$0.35 | -$0.80 |
Q4 2024 | 8 | -$1.00 | -$0.68 | -$0.85 |
Q1 2025 | 3 | -$1.63 | -$0.37 | -$0.84 |
Q2 2025 | 2 | -$1.64 | -$0.37 | -$0.85 |
Q3 2025 | 2 | -$1.79 | -$0.40 | -$0.92 |
Q4 2025 | 2 | -$1.82 | -$0.41 | -$0.94 |
Bicycle Therapeutics plc last posted its earnings results on Thursday, October 31st, 2024. The company reported $-0.74 earnings per share for the quarter, topping analysts' consensus estimates of $-0.78 by $0.04. The company had revenue of 2.68 M for the quarter and had revenue of 26.98 M for the year. Bicycle Therapeutics plc has generated $-5 earnings per share over the last year ($-5.08 diluted earnings per share) and currently has a price-to-earnings ratio of -6.09. Bicycle Therapeutics plc has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, February 18th, 2025 based on prior year's report dates.
Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
---|---|---|---|---|---|---|
10/31/2024 | Q3 2024 | -$0.78 | -$0.74 | 0.04 | $6.82 M | $2.68 M |
08/06/2024 | Q2 2024 | -$1.10 | -$0.77 | 0.33 | $6.13 M | $9.37 M |
05/02/2024 | Q1 2024 | -$1.26 | -$0.62 | 0.64 | $19.52 M | |
02/20/2024 | Q4 2023 | -$1.23 | -$1.16 | 0.07 | $5.33 M | |
11/02/2023 | Q3 2023 | -$1.06 | -$1.26 | -0.2 | $12.94 M | $5.35 M |
08/03/2023 | Q2 2023 | -$1.10 | -$1.41 | -0.31 | $5.78 M | $11.40 M |
05/04/2023 | Q1 2023 | -$1.06 | -$1.30 | -0.24 | $4.90 M | |
02/28/2023 | Q4 2022 | -$1.06 | -$1.01 | 0.05 | $3.19 M | |
11/03/2022 | Q3 2022 | -$0.98 | -$0.96 | 0.02 | $5.70 M | $3.04 M |
08/04/2022 | Q2 2022 | -$0.82 | -$0.90 | -0.08 | $3.69 M | $4.38 M |
05/05/2022 | Q1 2022 | -$0.70 | -$0.93 | -0.23 | $3.86 M | |
03/01/2022 | Q4 2021 | -$0.60 | -$0.63 | -0.03 | $3.77 M | |
11/04/2021 | Q3 2021 | -$0.67 | -$0.59 | 0.08 | $5.75 M | $4.33 M |
08/05/2021 | Q2 2021 | -$0.72 | -$0.74 | -0.02 | $2.31 M | $1.79 M |
05/06/2021 | Q1 2021 | -$0.66 | -$0.73 | -0.07 | $1.81 M | |
03/11/2021 | Q4 2020 | -$0.50 | -$0.83 | -0.33 | $3.85 M | |
11/05/2020 | Q3 2020 | -$0.66 | -$0.52 | 0.14 | $2.73 M | $3.84 M |
08/05/2020 | Q2 2020 | -$0.55 | -$0.67 | -0.12 | $2.36 M | $1.57 M |
05/07/2020 | Q1 2020 | $0.11 | -$0.63 | -0.74 | $1.13 M | |
03/10/2020 | Q4 2019 | -$0.52 | -$0.25 | 0.27 | $5.28 M |
Bicycle Therapeutics plc has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, February 18th, 2025 based off last year's report dates.
In the previous quarter, Bicycle Therapeutics plc (:BCYC) reported $-0.74 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.78 by $0.04.
The conference call for Bicycle Therapeutics plc's latest earnings report can be listened to online.
The conference call transcript for Bicycle Therapeutics plc's latest earnings report can be read online.
Bicycle Therapeutics plc (:BCYC) has a recorded annual revenue of $26.98 M.
Bicycle Therapeutics plc (:BCYC) has a recorded net income of $26.98 M. Bicycle Therapeutics plc has generated $-5.08 earnings per share over the last four quarters.
Bicycle Therapeutics plc (:BCYC) has a price-to-earnings ratio of -6.09 and price/earnings-to-growth ratio is -0.45.
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTED